A Single-Site, Phase 1/2, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Healthy Volunteers
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2007
At a glance
- Drugs AVX 502 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 31 Oct 2007 Status change from in progress to completed.
- 03 Aug 2007 Status changed from recruiting to in progress.
- 30 Jul 2007 Interim results have been reported.